Biosino Bio-Technology and Science Incorporation Past Earnings Performance
Past criteria checks 0/6
Biosino Bio-Technology and Science Incorporation has been growing earnings at an average annual rate of 43.6%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 3.4% per year.
Key information
43.6%
Earnings growth rate
43.6%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | -3.4% |
| Return on equity | -13.9% |
| Net Margin | -6.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Biosino Bio-Technology and Science Incorporation's (HKG:8247) Business And Shares Still Trailing The Industry
Oct 31
Biosino Bio-Technology and Science Incorporation's (HKG:8247) 26% Dip In Price Shows Sentiment Is Matching Revenues
Jun 27Shareholders Will Probably Be Cautious Of Increasing Biosino Bio-Technology and Science Incorporation's (HKG:8247) CEO Compensation At The Moment
Jun 21Biosino Bio-Technology and Science Incorporation (HKG:8247) Held Back By Insufficient Growth Even After Shares Climb 46%
Apr 22Is Biosino Bio-Technology and Science Incorporation (HKG:8247) Using Debt In A Risky Way?
Apr 01Biosino Bio-Technology and Science Incorporation's (HKG:8247) 31% Dip In Price Shows Sentiment Is Matching Revenues
Feb 08Some Confidence Is Lacking In Biosino Bio-Technology and Science Incorporation (HKG:8247) As Shares Slide 38%
Jul 31Revenue & Expenses Breakdown
How Biosino Bio-Technology and Science Incorporation makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 284 | -19 | 108 | 37 |
| 31 Mar 24 | 285 | -13 | 111 | 35 |
| 31 Dec 23 | 289 | -12 | 110 | 36 |
| 30 Sep 23 | 308 | -9 | 111 | 34 |
| 30 Jun 23 | 340 | 2 | 106 | 31 |
| 31 Mar 23 | 356 | 4 | 102 | 31 |
| 31 Dec 22 | 373 | 8 | 100 | 27 |
| 30 Sep 22 | 362 | 2 | 89 | 26 |
| 30 Jun 22 | 346 | -2 | 86 | 24 |
| 31 Mar 22 | 356 | -1 | 92 | 24 |
| 31 Dec 21 | 348 | -1 | 93 | 25 |
| 30 Sep 21 | 361 | 20 | 94 | 25 |
| 30 Jun 21 | 369 | 17 | 100 | 26 |
| 31 Mar 21 | 359 | 18 | 94 | 28 |
| 31 Dec 20 | 325 | 3 | 95 | 28 |
| 30 Sep 20 | 327 | -132 | 118 | 28 |
| 30 Jun 20 | 325 | -130 | 120 | 30 |
| 31 Mar 20 | 332 | -129 | 124 | 29 |
| 31 Dec 19 | 397 | -110 | 125 | 29 |
| 30 Sep 19 | 373 | 8 | 99 | 27 |
| 30 Jun 19 | 361 | 5 | 94 | 26 |
| 31 Mar 19 | 342 | 4 | 93 | 25 |
| 31 Dec 18 | 303 | -2 | 96 | 25 |
| 30 Sep 18 | 316 | 16 | 117 | 28 |
| 30 Jun 18 | 308 | 18 | 119 | 28 |
| 31 Mar 18 | 308 | 19 | 113 | 27 |
| 31 Dec 17 | 295 | 25 | 109 | 27 |
| 30 Sep 17 | 283 | 18 | 102 | 29 |
| 30 Jun 17 | 290 | 19 | 96 | 26 |
| 31 Mar 17 | 307 | 16 | 97 | 27 |
| 31 Dec 16 | 325 | 16 | 97 | 28 |
| 30 Sep 16 | 328 | 3 | 111 | 25 |
| 30 Jun 16 | 325 | 2 | 114 | 25 |
| 31 Mar 16 | 312 | 3 | 116 | 24 |
| 31 Dec 15 | 290 | 1 | 116 | 23 |
| 30 Sep 15 | 280 | 10 | 99 | 23 |
| 30 Jun 15 | 270 | 7 | 100 | 24 |
| 31 Mar 15 | 265 | 5 | 103 | 22 |
| 31 Dec 14 | 265 | 9 | 98 | 25 |
| 30 Sep 14 | 261 | 11 | 100 | 23 |
| 30 Jun 14 | 254 | 16 | 92 | 23 |
| 31 Mar 14 | 245 | 17 | 87 | 24 |
| 31 Dec 13 | 234 | 13 | 92 | 23 |
Quality Earnings: 8247 is currently unprofitable.
Growing Profit Margin: 8247 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8247 is unprofitable, but has reduced losses over the past 5 years at a rate of 43.6% per year.
Accelerating Growth: Unable to compare 8247's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8247 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 8247 has a negative Return on Equity (-13.87%), as it is currently unprofitable.